Praveen Tipirneni, Morphic Therapeutic CEO

Ab­b­Vie walks away from Mor­phic deal in af­ter­math of safe­ty sig­nal in pre­clin­i­cal test­ing

Ab­b­Vie is break­ing off its en­tire col­lab­o­ra­tion with Mor­phic Ther­a­peu­tic around oral in­te­grin in­hibitors, just months af­ter the phar­ma gi­ant al­ready cut away parts of the deal.

The news, dis­closed in an SEC fil­ing, marks a blow to Mor­phic’s small mol­e­cule ap­proach to block­ing in­te­grins, pro­teins that are in­tend­ed to help heal dam­age, but cause it when they run amok. Back in Oc­to­ber 2018, Ab­b­Vie kicked off their pact with $100 mil­lion in cash, with the goal of de­vel­op­ing a suite of fi­bro­sis drugs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.